Revelation Biosciences, Inc.
REVB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $923 | $1,318 | $859 | $606 |
| G&A Expenses | $1,020 | $1,143 | $1,236 | $1,148 |
| SG&A Expenses | $1,020 | $1,143 | $1,236 | $1,148 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $1,943 | $2,461 | $2,095 | $1,754 |
| Operating Income | -$1,943 | -$2,461 | -$2,095 | -$1,754 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $36 | $17 | $44 | $28 |
| Pre-Tax Income | -$1,907 | -$2,444 | -$2,051 | -$1,726 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,907 | -$2,444 | -$2,051 | -$1,726 |
| % Margin | – | – | – | – |
| EPS | -1.77 | -7.01 | -2.11 | -4.98 |
| % Growth | 74.8% | -232.2% | 57.6% | – |
| EPS Diluted | -1.77 | -7.01 | -2.11 | -4.98 |
| Weighted Avg Shares Out | 2,645 | 803 | 971 | 347 |
| Weighted Avg Shares Out Dil | 2,645 | 803 | 971 | 347 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $7 | $7 | $7 | $7 |
| EBITDA | -$1,900 | -$2,454 | -$2,088 | -$1,747 |
| % Margin | – | – | – | – |